



PIPELINE

Candidate: Lasofoxifene – Oral SERM

Monotherapy ●
 Combination Therapy ●●


► Breast Cancer

	Preclinical	Phase 1	Phase 2	Phase 3
● ELAINE 1: Lasofoxifene vs. Fulvestrant 				
●● ELAINE 2: Laso + Abemaciclib 				
●● ELAINE 3: (Registrational) Fulv + Abema vs. Laso + Abema 				
●● Laso + mTOR Inhibitor				
●● Laso + SARM				

In Planning
Enrollment Complete



▶ Treatment Resistant Tumors (non-ESR1^{mut}) and ESR1^{mut}



THE UNIVERSITY OF
CHICAGO



UNIVERSITY OF UTAH
HUNTSMAN
CANCER INSTITUTE

